Literature DB >> 22964438

Antiglutamic acid decarboxylase antibodies in children with encephalitis and status epilepticus.

Jainn-Jim Lin1, Kuang-Lin Lin, Shao-Hsuan Hsia, Huei-Shyong Wang, I-Jun Chou, Yun-Tong Lin.   

Abstract

Encephalitis may present with seizures or status epilepticus, and the etiology is usually presumed. Specific antibodies to ion channels, receptors, and other synaptic proteins were identified during the past decade. However, only a few studies investigated antiglutamic acid decarboxylase antibodies and antibodies to cell membrane ion channels or surface antigens in pediatric encephalitis and status epilepticus. We examined antibodies to glutamic acid decarboxylase and cell membrane ion channels or surface antigens in acute-phase serum from 17 children with encephalitis and status epilepticus. Antiglutamic acid decarboxylase antibody titers were compared with those of control children manifesting therapy-resistant epilepsy. Antiglutamic acid decarboxylase antibody titers were significantly higher in those with encephalitis and status epilepticus than in those with therapy-resistant epilepsy. No patient demonstrated antibodies to cell membrane ion channels or surface antigens. Six children exhibited positive antiglutamic acid decarboxylase antibodies. One child died, three manifested postencephalitic epilepsy with neurologic deficits, and two recovered well. Higher antiglutamic acid decarboxylase antibody titers were evident in the children with encephalitis and status epilepticus. Clinicians should be aware of the potential role of antiglutamic acid decarboxylase antibodies in children with encephalitis and status epilepticus.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964438     DOI: 10.1016/j.pediatrneurol.2012.06.013

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  5 in total

1.  Population-level evidence for an autoimmune etiology of epilepsy.

Authors:  Mei-Sing Ong; Isaac S Kohane; Tianxi Cai; Mark P Gorman; Kenneth D Mandl
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

Review 2.  Autoimmune seizures and epilepsy.

Authors:  Christian Geis; Jesus Planagumà; Mar Carreño; Francesc Graus; Josep Dalmau
Journal:  J Clin Invest       Date:  2019-02-04       Impact factor: 14.808

3.  Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study.

Authors:  I-Ching Chou; Chung-Hsing Wang; Wei-De Lin; Fuu-Jen Tsai; Che-Chen Lin; Chia-Hung Kao
Journal:  Diabetologia       Date:  2016-03-31       Impact factor: 10.122

4.  Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism.

Authors:  Kathleen Connery; Marie Tippett; Leanna M Delhey; Shannon Rose; John C Slattery; Stephen G Kahler; Juergen Hahn; Uwe Kruger; Madeleine W Cunningham; Craig Shimasaki; Richard E Frye
Journal:  Transl Psychiatry       Date:  2018-08-10       Impact factor: 6.222

5.  Effect of Antiepileptic Drugs for Acute and Chronic Seizures in Children with Encephalitis.

Authors:  Kuang-Lin Lin; Jainn-Jim Lin; Shao-Hsuan Hsia; Min-Liang Chou; Po-Cheng Hung; Huei-Shyong Wang
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.